1
|
Yang W, Wang J, Guo J, Dove A, Qi X, Bennett DA, Xu W. Association of Cognitive Reserve Indicator with Cognitive Decline and Structural Brain Differences in Middle and Older Age: Findings from the UK Biobank. J Prev Alzheimers Dis 2024; 11:739-748. [PMID: 38706290 PMCID: PMC11061039 DOI: 10.14283/jpad.2024.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 12/03/2023] [Indexed: 05/07/2024]
Abstract
BACKGROUND Cognitive reserve (CR) contributes to preserving cognition when facing brain aging and damage. CR has been linked to dementia risk in late life. However, the association between CR and cognitive changes and brain imaging measures, especially in midlife, is unclear. OBJECTIVE We aimed to explore the association of CR with cognitive decline and structural brain differences in middle and older age. DESIGN This longitudinal study was from the UK Biobank project where participants completed baseline surveys between 2006 to 2010 and were followed (mean follow-up: 9 years). SETTING A population-based study. PARTICIPANTS A total of 42,301 dementia-free participants aged 40-70 were followed-up to detect cognitive changes. A subsample (n=34,041) underwent brain magnetic resonance imaging scans. MEASUREMENTS We used latent class analysis to generate a CR indicator (categorized as high, moderate, and low) based on education, occupation, and multiple cognitively stimulating activities. Cognitive tests for global and domain-specific cognition were administrated at baseline and follow-up. Total brain, white matter, grey matter, hippocampal, and white matter hyperintensity volumes (TBV, WMV, GMV, HV, and WMHV) were assessed at the follow-up examination. Data were analyzed using mixed-effects models and analysis of covariance. RESULTS At baseline, 16,032 (37.9%), 10,709 (25.3%), and 15,560 (36.8%) participants had low, moderate, and high levels of CR, respectively. Compared with low CR, high CR was associated with slower declines in global cognition (β [95% confidence interval]: 0.10 [0.08, 0.11]), prospective memory (0.10 [0.06, 0.15]), fluid intelligence (0.07 [0.04, 0.10]), and reaction time (0.04 [0.02, 0.06]). Participants with high CR had lower TBV, WMV, GMV, and WMHV, but higher HV when controlling for global cognition (corrected P <0.01 for all). The significant relationships between CR and cognition and TBV were present among both middle-aged (<60 years) and older (≥60 years) participants. The CR-cognition association remained significant despite reductions in brain structural properties. CONCLUSIONS Higher CR is associated with slower cognitive decline, higher HV, and lower microvascular burden, especially in middle age. Individuals with high CR could tolerate smaller brain volumes while maintaining cognition. The benefit of CR for cognition is independent of structural brain differences. Our findings highlight the contribution of enhancing CR to helping compensate for neuroimaging alterations and ultimately prevent cognitive decline.
Collapse
Affiliation(s)
- W Yang
- Weili Xu, MD, PhD, Dept. of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Qixiangtai Road 22, Heping District, 300070, Tianjin, P.R. China; Aging Research Center, Karolinska Institutet, Tomtebodavägen 18A Floor 10, SE-171 65 Solna, Stockholm, Sweden. Phone: +46 8 524 858 26; ; Xiuying Qi, PhD, Dept. of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Qixiangtai Road 22, Heping District, 300070, Tianjin, P.R. China.
| | | | | | | | | | | | | |
Collapse
|
2
|
Darrow KR, McComas KN, Rajkumar AW, Dove A, Kluwe C, Murphy B, Gilbert J, Sinard R, Netterville J, Lockney NA, Cmelak AJ. Definitive Chemoradiation with Concurrent Carboplatin and Paclitaxel for HPV-Mediated Oropharyngeal Cancer (p16+ OPSCC): Survival and Local Control. Int J Radiat Oncol Biol Phys 2023; 117:e577. [PMID: 37785754 DOI: 10.1016/j.ijrobp.2023.06.1913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Standard therapy for locally advanced p16+ OPSCC with cisplatin and bilateral nodal RT results in substantial acute and late toxicities. De-intensification strategies are under active investigation, including the de-escalation of RT dose and field size and use of less toxic RT sensitizing agents. We present our single-institution experience with definitive chemoRT using weekly carboplatin and paclitaxel and modified RT. MATERIALS/METHODS A retrospective review of 139 consecutive patients with non-metastatic p16+ OPSCC treated with definitive chemoRT from 2013 to 2019 was performed. IMRT dose ranged from 60 to 70 Gy (median 69.96 Gy) to gross disease and 44 to 59.4 Gy (median 54.45 Gy) to elective nodal sites. Modified RT included dose reduction from 70 Gy EQD2 to 60-67.8 Gy EQD2 (2.0-2.2 Gy/fraction) and/or field modified contralateral neck. All patients received concurrent weekly paclitaxel (30 mg/m2) and carboplatin (AUC 1); 34 (24.5%) received induction chemotherapy. Patients were classified as low or intermediate risk based on HPV status, smoking history, and nodal staging per RTOG 0129 risk stratification. OS, local and regional RFS, and DSS were estimated using Kaplan-Meier method. RESULTS Median FU was 40.5 months. Of 139 pts, 96 were low and 43 were intermediate risk. Median age 61 yrs (range, 40-81 yrs). 125 pts were male and 14 were female. TNM staging: 29 pts (20.9%) were T1 (22 N1, 7 N2), 68 (48.9%) T2 (4 N0, 52 N1, 12 N2), 27 (19.4%) T3 (5 N0, 15 N1, 7 N2), and 15 (10.8%) T4 (2 N0, 2 N1, 10 N2, 1 N3). Median smoking history of 22.5 pack-yrs (range, 0.25-150 pack-yrs); 59 never smoked. LR recurrence was noted in 6/96 (6.3%) low risk and 7/43 (16.3%) intermediate risk pts. DM developed in 11/96 (11.5%) low risk and 8/43 (18.6%) intermediate risk pts. Synchronous LR recurrence and DM were noted in 1/96 (1%) low risk and 2/43 (4.7%) intermediate risk pts. The 3-year LRC was 93.6% (95% CI, 86.3-97.1) in the low-risk and 77.8% (95% CI, 61.4-87.8) in the intermediate-risk group. The 3-year OS was 95.4% (95% CI, 88.3-98.3) in the low-risk and 77.6% (95% CI, 61.3 to 87.7) in the intermediate-risk group. The 3-year DSS was 96.6% (95% CI, 89.7-98.9) in the low-risk and 86.8% (95% CI, 71.0-94.3) in the intermediate-risk group. CONCLUSION Definitive chemoRT for p16+ OPSCC with concurrent carboplatin and paclitaxel and a modified RT regimen designed to minimize acute and late effects of therapy demonstrated comparable outcomes to standard cisplatin-based chemoRT, such as report on RTOG 0129, with a high rate of LRC at 3 years. Our analysis suggests a role for a less intensive regimen using paclitaxel and carboplatin as a less toxic, effective alternative to cisplatin in the curative management of p16+ OPSCC, particularly in low-risk patients. Strategies for combating distant metastases are needed. Toxicity analysis planned to be presented separately.
Collapse
Affiliation(s)
- K R Darrow
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| | - K N McComas
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| | - A W Rajkumar
- Mayo Clinic Department of Radiation Oncology, Rochester, MN
| | - A Dove
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| | | | - B Murphy
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - J Gilbert
- Vanderbilt University Medical Center, Nashville, TN
| | - R Sinard
- Vanderbilt University Medical Center, Nashville, TN
| | | | - N A Lockney
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| | - A J Cmelak
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
3
|
McComas KN, Darrow KR, Rajkumar AW, Dove A, Kluwe C, Netterville J, Murphy B, Cmelak AJ. Tailoring Radiation to the Contralateral Neck for Midline HPV-Mediated Oropharyngeal Squamous Cell Carcinoma (p16+ OPSCC). Int J Radiat Oncol Biol Phys 2023; 117:e605-e606. [PMID: 37785825 DOI: 10.1016/j.ijrobp.2023.06.1974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) De-intensification strategies for locally advanced p16+ OPSCC are under active investigation, including omission of contralateral neck radiation (RT) for well-lateralized T1-2N0-2a. This study evaluates the outcomes of omitting contralateral neck nodal levels for p16+ OPSCC that are not well-lateralized. MATERIALS/METHODS A retrospective review was done of 134 consecutive patients with non-metastatic p16+ OPSCC that were not well-lateralized (< 1 cm from midline or ≥ 1 cm extension to soft palate or base of tongue) who were treated with definitive chemoradiation from 2013 to 2019. IMRT to an EQD2 6364-6735 cGy (200-220 cGy per fraction) was used to treat the primary tumor and ipsilateral or bilateral neck, with tailored nodal level coverage and dose, and with concurrent paclitaxel and carboplatin. Contralateral neck RT was tailored in 121 patients: omitted in 11, limited to level II in 9, and limited to level II and III in 101 (contralateral lower neck omitted); the remaining 13 had bilateral level II-IV neck RT. Local and regional recurrences were evaluated. RESULTS Median follow up was 45.34 months. Local and/or regional recurrence was noted in 9/134 (6.7%). 3 (2%) recurred in the contralateral neck in unirradiated tissue (out-of-field). All three were salvaged. The remaining 6 recurrences (4%) were in-field; one was at the primary site and 5 were nodal (all ipsilateral). 4 of the 5 regional recurrences were in a location that was treated to EQD2 7000 cGy (all had PET avid nodal disease upfront that was included in the high dose level); the other region of recurrence was treated to an EQD2 6353 cGy (the only recurrence in a never smoker). 4 of the 5 neck recurrences underwent neck dissection; one further underwent adjuvant RT to 5940 cGy in 33 fractions and remains disease-free. 2 of those who underwent salvage neck dissection alone subsequently developed distant metastases. The majority of first recurrences were distant, 19.4% (26/134). 3-year progression free survival (PFS) was 74.41% (95% CI, 65.63-81.26). Taken together, regional recurrence rate in the contralateral, unirradiated neck was 2.5% (3/121) and ultimate locoregional control was 99% (132/134). CONCLUSION Our tailored approach demonstrates a contralateral neck local control of 97.5% (118/121) regardless of tumor lateralization; those who recurred in unirradiated cervical lymph nodes were successfully salvaged. Limiting this analysis is moderate sample size and retrospective nature, but it raises important alternative de-escalation strategies (RT volume reduction) for p16+ OPSCC aside from dose reduction, which is under active investigation in phase II/III trials. Improved systemic therapies are needed to combat distant metastases. Prospective randomized clinical trials are needed for further evaluation of nodal omission for definitive chemoradiation of non-well-lateralized p16+ OPSCC.
Collapse
Affiliation(s)
- K N McComas
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| | - K R Darrow
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| | - A W Rajkumar
- Mayo Clinic Department of Radiation Oncology, Rochester, MN
| | - A Dove
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| | | | | | - B Murphy
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - A J Cmelak
- Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
4
|
Rajkumar A, Dove A, Golden D, Lockney N. Integration of Plan Review into Resident Clinical Didactics. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.06.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Khatiwada R, Bowring D, Chou AS, Sonnenschein A, Wester W, Mitchell DV, Braine T, Bartram C, Cervantes R, Crisosto N, Du N, Rosenberg LJ, Rybka G, Yang J, Will D, Kimes S, Carosi G, Woollett N, Durham S, Duffy LD, Bradley R, Boutan C, Jones M, LaRoque BH, Oblath NS, Taubman MS, Tedeschi J, Clarke J, Dove A, Hashim A, Siddiqi I, Stevenson N, Eddins A, O'Kelley SR, Nawaz S, Agrawal A, Dixit AV, Gleason JR, Jois S, Sikivie P, Sullivan NS, Tanner DB, Solomon JA, Lentz E, Daw EJ, Perry MG, Buckley JH, Harrington PM, Henriksen EA, Murch KW, Hilton GC. Axion Dark Matter Experiment: Detailed design and operations. Rev Sci Instrum 2021; 92:124502. [PMID: 34972408 DOI: 10.1063/5.0037857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 11/09/2021] [Indexed: 06/14/2023]
Abstract
Axion dark matter experiment ultra-low noise haloscope technology has enabled the successful completion of two science runs (1A and 1B) that looked for dark matter axions in the 2.66-3.1 μeV mass range with Dine-Fischler-Srednicki-Zhitnisky sensitivity [Du et al., Phys. Rev. Lett. 120, 151301 (2018) and Braine et al., Phys. Rev. Lett. 124, 101303 (2020)]. Therefore, it is the most sensitive axion search experiment to date in this mass range. We discuss the technological advances made in the last several years to achieve this sensitivity, which includes the implementation of components, such as the state-of-the-art quantum-noise-limited amplifiers and a dilution refrigerator. Furthermore, we demonstrate the use of a frequency tunable microstrip superconducting quantum interference device amplifier in run 1A, and a Josephson parametric amplifier in run 1B, along with novel analysis tools that characterize the system noise temperature.
Collapse
Affiliation(s)
- R Khatiwada
- Department of Physics, Illinois Institute of Technology, Chicago, Illinois 60616, USA and Fermilab Quantum Institute, Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Bowring
- Accelerator Physics Division, Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A S Chou
- Particle Physics Division, Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sonnenschein
- Particle Physics Division, Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - W Wester
- Particle Physics Division, Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D V Mitchell
- Particle Physics Division, Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - T Braine
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - C Bartram
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - R Cervantes
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - N Crisosto
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - N Du
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - L J Rosenberg
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - G Rybka
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J Yang
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - D Will
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - S Kimes
- Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - G Carosi
- Nuclear and Chemical Sciences Division, Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N Woollett
- Nuclear and Chemical Sciences Division, Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Durham
- Nuclear and Chemical Sciences Division, Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L D Duffy
- Accelerators and Electrodynamics Group, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R Bradley
- NRAO Technology Center, National Radio Astronomy Observatory, Charlottesville, Virginia 22903, USA
| | - C Boutan
- National Security Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M Jones
- National Security Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - B H LaRoque
- National Security Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - N S Oblath
- National Security Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M S Taubman
- National Security Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - J Tedeschi
- National Security Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - John Clarke
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - A Dove
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - A Hashim
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - I Siddiqi
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - N Stevenson
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - A Eddins
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S R O'Kelley
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S Nawaz
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - A Agrawal
- Department of Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - A V Dixit
- Department of Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J R Gleason
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - S Jois
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - P Sikivie
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - N S Sullivan
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - D B Tanner
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - J A Solomon
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - E Lentz
- Department of Physics, University of Göttingen, 37073 Göttingen, Germany
| | - E J Daw
- Department of Physics, University of Sheffield, Sheffield S10 2TN, United Kingdom
| | - M G Perry
- Department of Physics, University of Sheffield, Sheffield S10 2TN, United Kingdom
| | - J H Buckley
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
| | - P M Harrington
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
| | - E A Henriksen
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
| | - K W Murch
- Department of Physics, Washington University, St. Louis, Missouri 63130, USA
| | - G C Hilton
- Physical Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
| |
Collapse
|
6
|
Makepeace L, Wakefield D, Hubler A, Carnell M, Sharma A, Jiang B, Dove A, Garner W, Edmonston D, Ozdenerol E, Hanson R, Martin M, Pisu M, Schwartz D. Geospatial-socioeconomic Analysis of Patient Transportation-related Access Disparities to Radiation Treatment. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
7
|
Wakefield D, Makepeace L, Hubler A, Carnell M, Sharma A, Jiang B, Dove A, Garner W, Edmonston D, Ozdenerol E, Hanson R, Martin M, Pisu M, Schwartz D. Identifying Populations and Neighborhoods at High Risk for Hospital Admission-Driven Radiotherapy Interruption Using Geospatial Analytics. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
Wakefield DV, Carnell M, Jiang B, Dove A, Garner W, Edmonston D, Hubler A, Ozdenerol E, Hanson R, Pisu M, Schwartz DL, Schwarts DL. Abstract A124: Neighborhood, race and insurance predict for hospital admission during radiation therapy. Cancer Epidemiol Biomarkers Prev 2020. [DOI: 10.1158/1538-7755.disp19-a124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Background: Hospital admission during radiotherapy (ADRT) is associated with increased cost, interrupted treatment, and inferior outcomes. The purpose of this study was to benchmark patient ADRT rates, define socioeconomic predictors for ADRT, and geographically map ADRT rates on the neighborhood level across a large Mid-Southern catchment region served by a single academic cancer referral center. Methods: Demographic, clinical and treatment information were collected for all patients treated with radiation therapy (RT) at our center from January 1, 2015 to December 31, 2017. Occurrence of ADRT included inpatient and emergency room admissions. ADRT was categorized as causing “minor interruption” if ADRT was associated with postponement in 1-4 RT treatments. “Major interruption” was defined as postponement in 5 or more treatments. Patients with Medicaid or no insurance were categorized as “At-Risk”. Patient predicted income (PPI) was modeled using 2017 US Census data for annual household income by patient residence census tract, categorized into low (<$34k), middle, and high (>$67k) thirds. ADRT rates were compared across variables, analyzed using Pearson’s Chi square testing, and geomapped by patient residence at the neighborhood (census tract) level. Results: 3,729 patients were included. 2,032 (54.5%) were Caucasian, 1,577 African American (42.3%), and 120 (3.2%) other. Insurance status was defined as Commercial, Medicare, or At Risk in 1,794 (48.1%), 1,503 (40.3%), and 432 (11.6%) patients. The mean PPI was $49,951 (range $10,871-$177,857). A total of 83,306 fractions (median 24, IQR 11-30) were delivered with 7,107 (8.5%) total interruptions. 727 interruptions (mean 0.19, range 0-21) were due to ADRT in 197 patients (5.3%). Minor interruption rates were significantly elevated in At Risk patients v. those with Commercial or Medicare insurance (7.4% v 3.5% p=<0.0001; OR 2.21 [95%CI 1.47-3.31]), African American v. Caucasian patients (5.1% v 3.1% p=0.002; OR 1.66 [95%CI 1.19-2.32]), and low PPI v. high PPI patients (5.2% v 2.5% p=<0.0005; OR 2.17 [95%CI 1.39-3.39]). Major interruption rates were similar across all groups: At Risk v. Commercial or Medicare insurance (1.6% v 1.2% p=0.591; OR 1.25 [95%CI 0.55-2.79]), African American v. Caucasian ([1.3% v 1.4% p=0.74; OR 0.91 [95%CI 0.51-1.61]), and low PPI v. high PPI (1.4% v 1.3% p=0.93; OR 1.03 [95%CI 0.52-2.05]). Elevated minor interruption rates were geographically associated with low income, predominately African American neighborhoods across our treatment region. Conclusion: At our high-volume academic radiotherapy practice, hospital admission during RT correlated significantly with uninsured or Medicaid coverage status, African American race, and low predicted income and mapped to low income neighborhoods, suggesting limited care access for these populations. Major hotspot locations have been identified, setting the stage for targeted studies to close gaps in RT quality.
Citation Format: Daniel V Wakefield, Matthew Carnell, Bo Jiang, Austin Dove, Wesley Garner, Drucilla Edmonston, Adam Hubler, Esra Ozdenerol, Ryan Hanson, Maria Pisu, David L Schwartz, David L Schwarts. Neighborhood, race and insurance predict for hospital admission during radiation therapy [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr A124.
Collapse
Affiliation(s)
- Daniel V Wakefield
- 1University of Tennessee Health Science Center - Department of Radiation Oncology, Memphis, TN, USA,
| | - Matthew Carnell
- 2University of Tennessee Health Science Center - College of Medicine, Memphis, TN, USA,
| | - Bo Jiang
- 1University of Tennessee Health Science Center - Department of Radiation Oncology, Memphis, TN, USA,
| | - Austin Dove
- 3Vanderbilt University - Department of Radiation Oncology, Nashville, TN, USA,
| | - Wesley Garner
- 1University of Tennessee Health Science Center - Department of Radiation Oncology, Memphis, TN, USA,
| | - Drucilla Edmonston
- 1University of Tennessee Health Science Center - Department of Radiation Oncology, Memphis, TN, USA,
| | - Adam Hubler
- 2University of Tennessee Health Science Center - College of Medicine, Memphis, TN, USA,
| | - Esra Ozdenerol
- 4University of Memphis - Department of Earth Sciences, Memphis, TN, USA,
| | - Ryan Hanson
- 4University of Memphis - Department of Earth Sciences, Memphis, TN, USA,
| | - Maria Pisu
- 5University of Alabama Birmingham - Division of Preventive Medicine, Birmingham, AL, USA,
| | - David L Schwartz
- 1University of Tennessee Health Science Center - Department of Radiation Oncology, Memphis, TN, USA,
| | - David L Schwarts
- 6University of Tennessee Health Science Center - Department of Preventive Medicine, Memphis, TN, USA
| |
Collapse
|
9
|
Braine T, Cervantes R, Crisosto N, Du N, Kimes S, Rosenberg LJ, Rybka G, Yang J, Bowring D, Chou AS, Khatiwada R, Sonnenschein A, Wester W, Carosi G, Woollett N, Duffy LD, Bradley R, Boutan C, Jones M, LaRoque BH, Oblath NS, Taubman MS, Clarke J, Dove A, Eddins A, O'Kelley SR, Nawaz S, Siddiqi I, Stevenson N, Agrawal A, Dixit AV, Gleason JR, Jois S, Sikivie P, Solomon JA, Sullivan NS, Tanner DB, Lentz E, Daw EJ, Buckley JH, Harrington PM, Henriksen EA, Murch KW. Extended Search for the Invisible Axion with the Axion Dark Matter Experiment. Phys Rev Lett 2020; 124:101303. [PMID: 32216421 DOI: 10.1103/physrevlett.124.101303] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 01/23/2020] [Accepted: 02/18/2020] [Indexed: 06/10/2023]
Abstract
This Letter reports on a cavity haloscope search for dark matter axions in the Galactic halo in the mass range 2.81-3.31 μeV. This search utilizes the combination of a low-noise Josephson parametric amplifier and a large-cavity haloscope to achieve unprecedented sensitivity across this mass range. This search excludes the full range of axion-photon coupling values predicted in benchmark models of the invisible axion that solve the strong CP problem of quantum chromodynamics.
Collapse
Affiliation(s)
- T Braine
- University of Washington, Seattle, Washington 98195, USA
| | - R Cervantes
- University of Washington, Seattle, Washington 98195, USA
| | - N Crisosto
- University of Washington, Seattle, Washington 98195, USA
| | - N Du
- University of Washington, Seattle, Washington 98195, USA
| | - S Kimes
- University of Washington, Seattle, Washington 98195, USA
| | - L J Rosenberg
- University of Washington, Seattle, Washington 98195, USA
| | - G Rybka
- University of Washington, Seattle, Washington 98195, USA
| | - J Yang
- University of Washington, Seattle, Washington 98195, USA
| | - D Bowring
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A S Chou
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Khatiwada
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Sonnenschein
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - W Wester
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Carosi
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - N Woollett
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - L D Duffy
- Los Alamos National Laboratory, Los Alamos, California 87545, USA
| | - R Bradley
- National Radio Astronomy Observatory, Charlottesville, Virginia 22903, USA
| | - C Boutan
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M Jones
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - B H LaRoque
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - N S Oblath
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M S Taubman
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - J Clarke
- University of California, Berkeley, California 94720, USA
| | - A Dove
- University of California, Berkeley, California 94720, USA
| | - A Eddins
- University of California, Berkeley, California 94720, USA
| | - S R O'Kelley
- University of California, Berkeley, California 94720, USA
| | - S Nawaz
- University of California, Berkeley, California 94720, USA
| | - I Siddiqi
- University of California, Berkeley, California 94720, USA
| | - N Stevenson
- University of California, Berkeley, California 94720, USA
| | - A Agrawal
- University of Chicago, Chicago, Illinois 60637, USA
| | - A V Dixit
- University of Chicago, Chicago, Illinois 60637, USA
| | - J R Gleason
- University of Florida, Gainesville, Florida 32611, USA
| | - S Jois
- University of Florida, Gainesville, Florida 32611, USA
| | - P Sikivie
- University of Florida, Gainesville, Florida 32611, USA
| | - J A Solomon
- University of Florida, Gainesville, Florida 32611, USA
| | - N S Sullivan
- University of Florida, Gainesville, Florida 32611, USA
| | - D B Tanner
- University of Florida, Gainesville, Florida 32611, USA
| | - E Lentz
- University of Göttingen, Göttingen 37077, Germany
| | - E J Daw
- University of Sheffield, Sheffield S3 7RH, United Kingdom
| | - J H Buckley
- Washington University, St. Louis, Missouri 63130, USA
| | | | - E A Henriksen
- Washington University, St. Louis, Missouri 63130, USA
| | - K W Murch
- Washington University, St. Louis, Missouri 63130, USA
| |
Collapse
|
10
|
Lane S, Moncion M, Wakefield D, Dove A, Zhao L, Lukose R, Merchant T, Lucas J. Microbeam Proton Radiotherapy Allows for Greater Sparing of Periorbital Growth Plate and Vision Related Structures in Pediatric Cancer Patients with Orbital Primary Tumors. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Manole B, Wakefield D, Dove A, Dulaney C, Marcrom S, Schwartz D, Farmer M. Quality of Information Addressing Prostate Specific Antigen Screening on NCI Cancer Center and Public Health Organization Websites. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
|
13
|
|
14
|
Dove A, Hill B, Klawunn P, Waltho J, Backus S, McCrea RC. Spatial distribution and trends of total mercury in waters of the Great Lakes and connecting channels using an improved sampling technique. Environ Pollut 2012; 161:328-334. [PMID: 21715070 DOI: 10.1016/j.envpol.2011.06.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2011] [Accepted: 06/03/2011] [Indexed: 05/31/2023]
Abstract
Environment Canada recently developed a clean method suitable for sampling trace levels of metals in surface waters. The results of sampling for total mercury in the Laurentian Great Lakes between 2003 and 2009 give a unique basin-wide perspective of concentrations of this important contaminant and represent improved knowledge of mercury in the region. Results indicate that concentrations of total mercury in the offshore regions of the lakes were within a relatively narrow range from about 0.3 to 0.8 ng/L. The highest concentrations were observed in the western basin of Lake Erie and concentrations then declined towards the east. Compared to the offshore, higher levels were observed at some nearshore locations, particularly in lakes Erie and Ontario. The longer-term temporal record of mercury in Niagara River suspended sediments indicates an approximate 30% decrease in equivalent water concentrations since 1986.
Collapse
Affiliation(s)
- A Dove
- Water Quality Monitoring & Surveillance, Environment Canada, 867 Lakeshore Road, Burlington, ON L7R 4A6, Canada.
| | | | | | | | | | | |
Collapse
|
15
|
Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore ET, Robbins TW, Müller U. Sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Müller U, Dodds C, Dove A, van Loun A, Owen A, Regenthal R, Sahakian BJ, Bullmore ET, Clark L, Robbins TW. Dopaminergic modulation of manipulation processes in human working memory – critical involvement of D2 receptors and the ventral striatum. Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Abstract
OBJECTIVE To investigate the characteristics of incidents of aggression and violence directed towards staff in an urban UK emergency department. METHODS A retrospective review of incident report forms submitted over a 1 year period that collected data pertaining to the characteristics of assailants, the outcome of incidents, and the presence of possible contributory factors. RESULTS A total of 218 incident reports were reviewed. It was found that the majority of assailants were patients, most were male, and the median age was 32 years. Assailants were more likely to live in deprived areas than other patients and repeat offenders committed 45 of the incidents reported during the study period. The incident report indicated that staff thought the assailant was under the influence of alcohol on 114 occasions. Incidents in which the assailant was documented to have expressed suicidal ideation or had been referred to the psychiatric services were significantly more likely to describe physical violence, as were those incidents in which the assailant was female. CONCLUSION Departments should seek to monitor individuals responsible for episodes of violence and aggression in order to detect repeat offenders. A prospective study comprising post-incident reviews may provide a valuable insight into the causes of violence and aggression.
Collapse
Affiliation(s)
- A James
- Department of Clinical Psychiatry and Psychotherapy, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
| | | | | |
Collapse
|
18
|
Dove A. Patents not key barrier to AIDS therapy. Nat Med 2001; 7:1262. [PMID: 11726942 DOI: 10.1038/nm1201-1262a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
19
|
|
20
|
|
21
|
|
22
|
Dove A. US throws money at TSE research. Nat Med 2001; 7:1075. [PMID: 11590408 DOI: 10.1038/nm1001-1075a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
23
|
|
24
|
|
25
|
Dove A. ES cells leave their imprint. Nat Biotechnol 2001; 19:739. [PMID: 11491108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
26
|
Dove A. Stem cell researchers ponder worst-case scenario. Nat Med 2001; 7:876. [PMID: 11479601 DOI: 10.1038/90877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
27
|
Dove A. Report predicts burgeoning vaccine markets. Nat Med 2001; 7:877. [PMID: 11479604 DOI: 10.1038/90884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
28
|
Dove A. Piezoelectric arrays. Nat Biotechnol 2001; 19:739. [PMID: 11491109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
29
|
|
30
|
|
31
|
|
32
|
|
33
|
|
34
|
|
35
|
Dove A. New reporting rules for gene therapy and xeno trials. Nat Med 2001; 7:265. [PMID: 12422866 DOI: 10.1038/85382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
36
|
|
37
|
|
38
|
Dove A. Biotech weighs up the options in obesity. Nat Biotechnol 2001; 19:25-8. [PMID: 11135547 DOI: 10.1038/83465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
39
|
|
40
|
Dove A. New database could lead to antibiotic overuse. Nat Med 2000; 6:1304. [PMID: 11100098 DOI: 10.1038/82091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
41
|
Dove A. New bioterrorism institute enters burgeoning field. Nat Med 2000; 6:1304. [PMID: 11100099 DOI: 10.1038/82093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
42
|
Dove A. USDA gives ground over lab animals. Nat Med 2000; 6:1197. [PMID: 11062513 DOI: 10.1038/81263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
43
|
Abstract
Despite recent accomplishments, significant challenges remain before cloning can become a routine part of transgenic animal production.
Collapse
|
44
|
Dove A. NIH 'glues' cell biologists together. Nat Med 2000; 6:1072. [PMID: 11017123 DOI: 10.1038/80380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
45
|
|
46
|
Dove A. AIDS defined as unique military threat. Nat Med 2000; 6:949. [PMID: 10973297 DOI: 10.1038/79618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Dove A. GAO reports on CFS funding controversy. Nat Med 2000; 6:846. [PMID: 10932206 DOI: 10.1038/78579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
48
|
|
49
|
Dove A. HHS criticizes research centers for inaction on patient safety. Nat Med 2000; 6:611. [PMID: 10835657 DOI: 10.1038/76153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
50
|
|